| |
Here's the latest news from IMMU:
FEDERAL FILINGS
10/01 Immunomedics' NIH Grant/To Develop Cancer Product
FORM 10Q PERIOD ENDED: 06/30/96
SEC RCVD DATE: 09/30/96
ISSUER: IMMUNOMEDICS INC.
SYMBOL: IMMU
Last month, Immunomedics was awarded a Phase II Small Business
Innovation Research (SBIR) grant from the National Cancer Institute
(NCI) of the National Institutes of Health (NIH), totaling $750,000 and
payable over two years.
The company says it will use the funds to develop a yttrium-90
radiolabeled humanized LL2 antibody for clinical radioimmunotherapy of
radiosensitive non-Hodgkin's lymphoma. The research aims to identify
the optimal form of the radioimmunoconjugate and advance this product
through a Phase I/II trial.
Separately, Immunomedics says that it has also applied for two
$100,000 SBIR Phase I grants, each of which is concerned with therapy
applications using the company's antibodies. The company indicates that
each of the applications has received recommendation for funding in the
NCI peer review process.
The first application covers the identification of an optimal
drug conjugate anti-PCP antibody to be used for treatment of AIDS
patients suffering from this type of infection.
The second application covers the development of radioiodinated
antibodies, prepared using novel chemistries, from which the iodine-131
is retained for extended periods inside tumor cells, like yttrium-90,
for enhanced iodine-131 radioimmunotherapy.
/FEDERAL FILINGS CONTACTS: (202) 393-7856 FOR EDITORIAL,
(800) 487-6162 FOR DOCUMENT SALES,
(202) 628-8990 FOR NEWSWIRE SALES,
& (888) FED-FILE FOR TECHNICAL SUPPORT./
(END) FEDERAL FILINGS-DOW JONES NEWS 10-01-96
10:57 |
|
